Stifel on NewAmsterdam Pharma Co NV (NAMS): 'the risk/reward is very compelling'
Stifel analyst James Condulis reiterated a Buy rating and $50.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)